On Friday, Arcutis Biotherapeutics got an upgrade to its Relative Strength (RS) Rating, from 76 to 83.
Hone Your Stock-Picking Skills By Focusing On These Factors
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the best stocks typically have an RS Rating north of 80 in the early stages of their moves.
Arcutis Biotherapeutics is working on a consolidation with a 17.75 entry. See if the stock can clear the breakout price in volume at least 40% above average.
The company reported 0% EPS growth last quarter, while sales growth came in at 33%.
Arcutis Biotherapeutics holds the No. 64 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
